Drug Type Diagnostic radiopharmaceuticals |
Synonyms- |
Target |
Action agonists |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas- |
Active Indication- |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseClinical |
First Approval Date- |
Regulation- |
Phase 1 | Congenital Hyperinsulinism ABCC8 gene mutations | 16 | (Congenital Hyperinsulinism) | fxmfgssypd(diceuhtefl) = awdlctxbdr lklajlmisq (pdczkuluqz, 64.80 - 99.20) View more | Positive | 27 May 2026 | |
Not Applicable | Diabetes Mellitus, Type 1 GLP-1 receptor | - | 68 Ga-exendin4 (Type 1 Diabetes Patients) | unbuxdpiyv(anxbreaaod) = The C-peptide response to the MMT in T1DM patients, as assessed by an ultrasensitive ELISA, was negligible (mean C-peptide concentration during the MMT: 4.2±2.9 pmol/l) and its modeling impossible, whereas the OB displayed a robust BCFxM (173±31) wtrxfkrhcs (yrtreqwusd ) | Positive | 06 Oct 2023 | |
68 Ga-exendin4 (Obese Subjects) |





